MX2023005305A - Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer. - Google Patents
Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer.Info
- Publication number
- MX2023005305A MX2023005305A MX2023005305A MX2023005305A MX2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A MX 2023005305 A MX2023005305 A MX 2023005305A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclopropyl
- carboxamide
- triazol
- pyrrolidine
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112609P | 2020-11-11 | 2020-11-11 | |
| PCT/US2020/062627 WO2022103411A1 (en) | 2020-11-11 | 2020-11-30 | 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005305A true MX2023005305A (es) | 2023-05-25 |
Family
ID=73839136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005305A MX2023005305A (es) | 2020-11-11 | 2020-11-30 | Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230391766A1 (https=) |
| EP (1) | EP4244218A1 (https=) |
| JP (2) | JP7654075B2 (https=) |
| KR (1) | KR20230106637A (https=) |
| CN (1) | CN116783183B (https=) |
| AU (1) | AU2020476996A1 (https=) |
| CA (1) | CA3197092A1 (https=) |
| IL (1) | IL302678A (https=) |
| MX (1) | MX2023005305A (https=) |
| WO (1) | WO2022103411A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119677735A (zh) * | 2022-05-11 | 2025-03-21 | 基因泰克公司 | 作为vhl配体的苯并噻唑化合物 |
| WO2025162250A1 (zh) * | 2024-02-04 | 2025-08-07 | 贝达药业股份有限公司 | 取代的三环化合物及其用途 |
| WO2025228305A1 (zh) * | 2024-04-28 | 2025-11-06 | 中国科学院上海药物研究所 | 一种蛋白降解剂缀合物及其偶联物 |
| WO2026012475A1 (en) * | 2024-07-12 | 2026-01-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Vhl ligands and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2013106646A2 (en) * | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| GB2554071A (en) * | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| CN110573507B (zh) * | 2017-04-14 | 2023-11-14 | 邓迪大学 | 小分子 |
| US11547759B2 (en) * | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
-
2020
- 2020-11-30 KR KR1020237018547A patent/KR20230106637A/ko active Pending
- 2020-11-30 CA CA3197092A patent/CA3197092A1/en active Pending
- 2020-11-30 EP EP20825085.2A patent/EP4244218A1/en active Pending
- 2020-11-30 JP JP2023528057A patent/JP7654075B2/ja active Active
- 2020-11-30 MX MX2023005305A patent/MX2023005305A/es unknown
- 2020-11-30 WO PCT/US2020/062627 patent/WO2022103411A1/en not_active Ceased
- 2020-11-30 CN CN202080108318.5A patent/CN116783183B/zh active Active
- 2020-11-30 IL IL302678A patent/IL302678A/en unknown
- 2020-11-30 AU AU2020476996A patent/AU2020476996A1/en active Pending
-
2023
- 2023-05-09 US US18/195,134 patent/US20230391766A1/en active Pending
-
2025
- 2025-01-23 JP JP2025009859A patent/JP2025063287A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022103411A1 (en) | 2022-05-19 |
| US20230391766A1 (en) | 2023-12-07 |
| KR20230106637A (ko) | 2023-07-13 |
| AU2020476996A1 (en) | 2023-06-29 |
| CN116783183A (zh) | 2023-09-19 |
| CA3197092A1 (en) | 2022-05-19 |
| CN116783183B (zh) | 2026-03-20 |
| JP7654075B2 (ja) | 2025-03-31 |
| IL302678A (en) | 2023-07-01 |
| JP2023549187A (ja) | 2023-11-22 |
| EP4244218A1 (en) | 2023-09-20 |
| JP2025063287A (ja) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005305A (es) | Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer. | |
| PE20210642A1 (es) | Inhibidores de pd-1/pd-l1 | |
| NZ594981A (en) | Hepatitis c virus inhibitors | |
| UY24434A1 (es) | Nuevos imidazoles sustituidos con cicloalquilo | |
| PE20091673A1 (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion | |
| CY1113547T1 (el) | Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c | |
| EA201000196A1 (ru) | Кристаллическая форма дигидрохлорида метил((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((метоксикарбонил)амино)-3-метилбутаноил)-2-пирролидинил)-1н-имидазол-5-ил)-4-бифенилил)-1н-имидазол-2-ил)-1-пирролидинил)карбонил)-2-метилпропил)карбамата | |
| NZ598125A (en) | Apaf-1 inhibitor compounds | |
| NZ710567A (en) | Antiviral compounds | |
| PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| RU2014152276A (ru) | Замещенные пирролидины в качестве ингибиторов фактора xia для лечения тромбоэмболических заболеваний | |
| PE20120546A1 (es) | Inhibidores del virus de la hepatitis c | |
| NZ595073A (en) | Proline derivatives as cathepsin inhibitors | |
| PH12016502242B1 (en) | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor | |
| NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
| PE20120533A1 (es) | Inhibidores del virus de la hepatitis c | |
| FI3658141T3 (fi) | Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella | |
| NZ594163A (en) | Pyranose derivatives of pestcidal 1,2,4-triazoles | |
| EA200802329A1 (ru) | Производные триазола ii | |
| AR078411A1 (es) | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende | |
| NZ611528A (en) | Neprilysin inhibitors | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| CY1117978T1 (el) | Θεραπευτικες χρησεις ενωσεων που εχουν συνδυασμενη δραστικοτητα sert, 5-ητ3 και 5-ητ1a | |
| AR072262A1 (es) | COMBINACION -408, QUE COMPRENDE N-CICLOHEXIL-N3-[2-(3-FLUOROFENIL)ETIL]-N-(2-{[2-(4-HIDROXI-2-OXO-2,3-DIHIDRO-1,3-BENZOTIAZOL-7-IL)ETIL]AMINO}ETIL- beta-ALANINAMIDA.USO. METODO. CONJUNTO DE ELEMENTOS. COMPOSICION FARMACEUTICA. INTERMEDIARIO. | |
| MX2009011881A (es) | Nueva composicion farmaceutica. |